Nightingale
Research
Trials
Now
Now
Recruiting
Effect of Orforglipron on patients with established CVD and/or CKD.
- Age > 50 years
- BMI > 25 kg/m²
- Oral tablet daily
- Not taking Ozempic/Mounjaro
Heart Disease, Diabetes and High Blood Pressure Study
Adelaide SA | Frankston VIC
Effect of Vicadrostat and Empagliflozin in patients with HF and EF>40%
- Age > 18 years
- History of heart attack, stroke or vascular disease
- Oral tablet daily
Symptomatic Heart Failure Study
Frankston VIC
Effect of Vicadrostat and Empagliflozin in patients with HF and EF>40%.
- Age > 18 years
- Elevated heart failure bloods (tested at screening visit)
- Taking diuretic medication
- Oral tablet daily
Assess Baxdrostat in combination with Dapagliflozin on renal outcomes and CV mortality in participants with CKD and high blood pressure.
- Age > 18 years
- Reduced kidney function
- Taking blood pressure medication
Upcoming Trials
▼
Adelaide SA
- Age > 18 years
- Age < 55 years
Adelaide SA
Effect of Muvalaplin on the reduction of major adverse cardiovascular events in adults with elevated Lipoprotein(a), who have had a prior atherosclerotic cardiovascular event, or are at risk for a first atherosclerotic cardiovascular event.
- Age > 18 years
- Lp(a) blood test taken at screening visit
Ongoing Trials
(Enrolment Closed)
▼
Adelaide SA
Effect of Retatrutide on participants without type 2 diabetes who have obesity and OSA.
- BMI > 27 kg/m²
- Type 2 diabetes
Adelaide SA
Effect of Retatrutide on participants with or without type 2 diabetes who have obesity.
- BMI > 35 kg/m²
- Diabetic or non-diabetic
Adelaide SA
Effect of Retatrutide on participants without type 2 diabetes who have obesity and knee OA.
- BMI > 30 kg/m²
- Weight-related comorbidities: hypertension, high cholesterol, knee pain / osteoarthritis
Completed Trials
▼
Adelaide SA | Goolwa SA
Effect of Tirzapetide vs Dulaglutide on CV events in patients with Type 2 Diabetes.
- Age > 40 years
- BMI > 25 kg/m²
